Caribou Biosciences Inc (CRBU)

$2.14 0.00 (N/A)
Market Cap 210.26M
Revenue (ttm) 11.16M
Net Income (ttm) -148.13M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,327.33%
Debt to Equity Ratio 0.00
Volume 1,923,700
Avg Vol 1,362,426
Day's Range N/A - N/A
Shares Out 99.18M
Stochastic %K 62%
Beta 2.27
Analysts Strong Sell
Price Target $18.55

Company Profile

Caribou Biosciences, Inc. operates as a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. It offers a genome-editing platform based on novel CRISPR hybrid RNA-DNA genome-editing technology that enables precise genome editing of allogeneic cell therapies. The company develops Vispacabtagene Regedleucel, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Ho...

Industry: Biotechnology
Sector: Healthcare
Phone: 510 982 6030
Address:
2929 7th Street, Suite 105, Berkeley, United States
postless
postless May. 14 at 11:46 PM
$CRBU got my money
0 · Reply
biochirp
biochirp May. 14 at 6:35 PM
$CRBU analyst upgrades ahead of Pfizer decision Pumping their own books for liquidity? ☠️
1 · Reply
NicaInvest85
NicaInvest85 May. 14 at 6:07 PM
$CRBU Caribou Biosciences (CRBU) stock is up following a significant analyst upgrade to revenue forecasts and recent positive regulatory progress, including FDA clearance of their IND application for CB-011, an allogeneic CAR-T therapy for multiple myeloma.
0 · Reply
Ewak21
Ewak21 May. 14 at 4:20 PM
$CRBU something must be cooking! I just hope it is not wishfull thinking…
0 · Reply
StockJayC
StockJayC May. 14 at 4:18 PM
$CRBU Sitting on the sidelines for the past 2 years waiting to finally realise some decent gains! GLTA!
0 · Reply
Tdorsey1776
Tdorsey1776 May. 14 at 4:12 PM
$CRBU Next catalyst?
0 · Reply
vu_jade
vu_jade May. 14 at 3:46 PM
$CRBU ready to explode here
1 · Reply
MagisterofMarkets
MagisterofMarkets May. 13 at 12:42 PM
$CRBU hilarious that HC wainwright been reiterating their buy rating since the IPO. They must be bagholding like the res of us😂
0 · Reply
Mogeyman
Mogeyman May. 11 at 9:40 PM
$CRBU Now. What's going on?
0 · Reply
ebodonicus
ebodonicus May. 11 at 2:28 PM
$CRBU whoa. Whats going on
1 · Reply
Latest News on CRBU
Caribou Biosciences to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference

May 13, 2026, 4:05 PM EDT - 2 days ago

Caribou Biosciences to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference

Caribou Biosciences Transcript: Bank of America Global Healthcare Conference 2026

May 13, 2026, 11:40 AM EDT - 2 days ago

Caribou Biosciences Transcript: Bank of America Global Healthcare Conference 2026

Caribou Biosciences to Highlight Vispa-cel and CB-011 Programs During Oral Presentations at the 2026 European Hematology Association (EHA) Annual Meeting

May 12, 2026, 9:30 AM EDT - 3 days ago

Caribou Biosciences to Highlight Vispa-cel and CB-011 Programs During Oral Presentations at the 2026 European Hematology Association (EHA) Annual Meeting

Caribou Biosciences price target raised to $11 from $9 at H.C. Wainwright

2026-05-11T10:25:24.000Z - 4 days ago

Caribou Biosciences price target raised to $11 from $9 at H.C. Wainwright

Caribou Biosciences Reports First Quarter 2026 Financial Results and Provides Business Update

May 7, 2026, 4:05 PM EDT - 8 days ago

Caribou Biosciences Reports First Quarter 2026 Financial Results and Provides Business Update

Caribou Biosciences to Participate in the BofA Securities 2026 Health Care Conference

May 5, 2026, 4:05 PM EDT - 10 days ago

Caribou Biosciences to Participate in the BofA Securities 2026 Health Care Conference

Caribou Biosciences Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) Designation to CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy

Mar 31, 2026, 8:00 AM EDT - 6 weeks ago

Caribou Biosciences Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) Designation to CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy

Caribou Biosciences Transcript: Leerink Global Healthcare Conference 2026

Mar 10, 2026, 8:00 AM EDT - 2 months ago

Caribou Biosciences Transcript: Leerink Global Healthcare Conference 2026

Caribou Biosciences price target raised to $13 from $11 at Evercore ISI

2026-03-09T12:14:17.000Z - 2 months ago

Caribou Biosciences price target raised to $13 from $11 at Evercore ISI

Caribou Biosciences reports Q4 EPS (28c) vs. (39c) last year

2026-03-05T21:28:29.000Z - 2 months ago

Caribou Biosciences reports Q4 EPS (28c) vs. (39c) last year

Caribou Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Mar 5, 2026, 4:05 PM EST - 2 months ago

Caribou Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Caribou Biosciences Transcript: Citi’s 2026 Virtual Oncology Leadership Summit

Feb 19, 2026, 10:45 AM EST - 3 months ago

Caribou Biosciences Transcript: Citi’s 2026 Virtual Oncology Leadership Summit

Watchmaker Genomics Licenses CRISPR-Cas9 Intellectual Property from Caribou Biosciences to Increase Throughput and Reduce Sequencing Cost per Sample

Feb 17, 2026, 8:00 AM EST - 3 months ago

Watchmaker Genomics Licenses CRISPR-Cas9 Intellectual Property from Caribou Biosciences to Increase Throughput and Reduce Sequencing Cost per Sample

Caribou Biosciences to Participate in Upcoming Investor Conferences

Feb 12, 2026, 4:05 PM EST - 3 months ago

Caribou Biosciences to Participate in Upcoming Investor Conferences

Caribou Biosciences Announces Late-Breaking Presentations at the 2026 Tandem Meetings of ASTCT® and CIBMTR®

Feb 4, 2026, 8:00 AM EST - 3 months ago

Caribou Biosciences Announces Late-Breaking Presentations at the 2026 Tandem Meetings of ASTCT® and CIBMTR®

Caribou Biosciences initiated with a Buy at Clear Street

2026-02-02T21:25:29.000Z - 3 months ago

Caribou Biosciences initiated with a Buy at Clear Street

Caribou Biosciences price target lowered to $6 from $8 at BofA

2026-01-06T15:15:25.000Z - 4 months ago

Caribou Biosciences price target lowered to $6 from $8 at BofA

Caribou Biosciences Transcript: The 67th American Society of Hematology (ASH) Annual Meeting

Dec 6, 2025, 7:30 AM EST - 5 months ago

Caribou Biosciences Transcript: The 67th American Society of Hematology (ASH) Annual Meeting

Caribou Biosciences Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 2, 2025, 8:45 AM EST - 5 months ago

Caribou Biosciences Transcript: Evercore ISI 8th Annual HealthCONx Conference

Caribou Biosciences to Host In-Person and Virtual KOL Event at ASH 2025

Dec 1, 2025, 4:05 PM EST - 5 months ago

Caribou Biosciences to Host In-Person and Virtual KOL Event at ASH 2025

Caribou Biosciences reports Q3 EPS (30c) vs. (38c) last year

2025-11-12T22:25:13.000Z - 6 months ago

Caribou Biosciences reports Q3 EPS (30c) vs. (38c) last year

Caribou Biosciences Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 12, 2025, 4:05 PM EST - 6 months ago

Caribou Biosciences Reports Third Quarter 2025 Financial Results and Provides Business Update

Caribou Biosciences price target raised to $9 from $3 at H.C. Wainwright

2025-11-05T11:21:02.000Z - 6 months ago

Caribou Biosciences price target raised to $9 from $3 at H.C. Wainwright

Caribou Biosciences price target raised to $8 from $5 at Citi

2025-11-03T15:15:34.000Z - 6 months ago

Caribou Biosciences price target raised to $8 from $5 at Citi

Caribou Biosciences Transcript: Study Result

Nov 3, 2025, 8:00 AM EST - 6 months ago

Caribou Biosciences Transcript: Study Result

Caribou Biosciences announces results from CaMMouflage Phase 1 trial

2025-11-03T12:22:51.000Z - 6 months ago

Caribou Biosciences announces results from CaMMouflage Phase 1 trial

Caribou Biosciences announces results from ANTLER phase 1 trial of vispa-cel

2025-11-03T12:15:12.000Z - 6 months ago

Caribou Biosciences announces results from ANTLER phase 1 trial of vispa-cel

Caribou Biosciences Announces Positive Data from CaMMouflage Phase 1 Trial of CB-011 in Multiple Myeloma

Nov 3, 2025, 7:00 AM EST - 6 months ago

Caribou Biosciences Announces Positive Data from CaMMouflage Phase 1 Trial of CB-011 in Multiple Myeloma

Caribou Biosciences Announces Positive Data from ANTLER Phase 1 Trial Demonstrating Efficacy and Durability of Vispa-cel (CB-010), an Allogeneic CAR-T Cell Therapy, on Par with Autologous CAR-T Cell Therapies

Nov 3, 2025, 7:00 AM EST - 6 months ago

Caribou Biosciences Announces Positive Data from ANTLER Phase 1 Trial Demonstrating Efficacy and Durability of Vispa-cel (CB-010), an Allogeneic CAR-T Cell Therapy, on Par with Autologous CAR-T Cell Therapies

Caribou Biosciences to Host Webcast to Report New Data Updates from Two Allogeneic CAR-T Cell Therapy Programs in Lymphoma and Multiple Myeloma

Nov 2, 2025, 4:00 PM EST - 6 months ago

Caribou Biosciences to Host Webcast to Report New Data Updates from Two Allogeneic CAR-T Cell Therapy Programs in Lymphoma and Multiple Myeloma

Caribou Biosciences Transcript: Citi's Biopharma Back to School Conference

Sep 3, 2025, 2:30 PM EDT - 9 months ago

Caribou Biosciences Transcript: Citi's Biopharma Back to School Conference

Caribou Biosciences to Participate in the Citi 2025 Biopharma Back to School Conference

Aug 25, 2025, 4:05 PM EDT - 9 months ago

Caribou Biosciences to Participate in the Citi 2025 Biopharma Back to School Conference

Caribou Biosciences reports Q2 EPS (35c), one estimate (42c)

2025-08-12T21:00:25.000Z - 9 months ago

Caribou Biosciences reports Q2 EPS (35c), one estimate (42c)

Caribou Biosciences Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 12, 2025, 4:05 PM EDT - 9 months ago

Caribou Biosciences Reports Second Quarter 2025 Financial Results and Provides Business Update

Caribou Biosciences Transcript: Jefferies Global Healthcare Conference 2025

Jun 4, 2025, 9:20 AM EDT - 1 year ago

Caribou Biosciences Transcript: Jefferies Global Healthcare Conference 2025

Caribou Biosciences to Participate in the Jefferies Global Healthcare Conference

May 28, 2025, 4:00 PM EDT - 1 year ago

Caribou Biosciences to Participate in the Jefferies Global Healthcare Conference

Caribou Biosciences Transcript: Bank of America 2025 Healthcare Conference

May 13, 2025, 5:35 PM EDT - 1 year ago

Caribou Biosciences Transcript: Bank of America 2025 Healthcare Conference

Caribou Biosciences files $300M mixed securities shelf

2025-05-08T21:05:17.000Z - 1 year ago

Caribou Biosciences files $300M mixed securities shelf

Caribou Biosciences Reports First Quarter 2025 Financial Results and Provides Business Update

May 8, 2025, 4:05 PM EDT - 1 year ago

Caribou Biosciences Reports First Quarter 2025 Financial Results and Provides Business Update

Caribou Biosciences to Participate in the BofA Securities 2025 Health Care Conference

May 6, 2025, 4:00 PM EDT - 1 year ago

Caribou Biosciences to Participate in the BofA Securities 2025 Health Care Conference

Caribou Biosciences price target lowered to $9 from $11 at BofA

2025-04-28T11:39:07.000Z - 1 year ago

Caribou Biosciences price target lowered to $9 from $11 at BofA

Caribou Biosciences Announces Strategic Pipeline Prioritization with Focus on CB-010 and CB-011 Oncology Programs

Apr 24, 2025, 4:15 PM EDT - 1 year ago

Caribou Biosciences Announces Strategic Pipeline Prioritization with Focus on CB-010 and CB-011 Oncology Programs

Caribou Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Mar 10, 2025, 4:05 PM EDT - 1 year ago

Caribou Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

postless
postless May. 14 at 11:46 PM
$CRBU got my money
0 · Reply
biochirp
biochirp May. 14 at 6:35 PM
$CRBU analyst upgrades ahead of Pfizer decision Pumping their own books for liquidity? ☠️
1 · Reply
NicaInvest85
NicaInvest85 May. 14 at 6:07 PM
$CRBU Caribou Biosciences (CRBU) stock is up following a significant analyst upgrade to revenue forecasts and recent positive regulatory progress, including FDA clearance of their IND application for CB-011, an allogeneic CAR-T therapy for multiple myeloma.
0 · Reply
Ewak21
Ewak21 May. 14 at 4:20 PM
$CRBU something must be cooking! I just hope it is not wishfull thinking…
0 · Reply
StockJayC
StockJayC May. 14 at 4:18 PM
$CRBU Sitting on the sidelines for the past 2 years waiting to finally realise some decent gains! GLTA!
0 · Reply
Tdorsey1776
Tdorsey1776 May. 14 at 4:12 PM
$CRBU Next catalyst?
0 · Reply
vu_jade
vu_jade May. 14 at 3:46 PM
$CRBU ready to explode here
1 · Reply
MagisterofMarkets
MagisterofMarkets May. 13 at 12:42 PM
$CRBU hilarious that HC wainwright been reiterating their buy rating since the IPO. They must be bagholding like the res of us😂
0 · Reply
Mogeyman
Mogeyman May. 11 at 9:40 PM
$CRBU Now. What's going on?
0 · Reply
ebodonicus
ebodonicus May. 11 at 2:28 PM
$CRBU whoa. Whats going on
1 · Reply
NicaInvest85
NicaInvest85 May. 8 at 2:46 PM
$CRBU come on CRBU pick up the steam
0 · Reply
NicaInvest85
NicaInvest85 May. 8 at 2:40 PM
$CRBU $MRNA picking up steam due to the hantavirus.
0 · Reply
Jidane
Jidane May. 8 at 11:17 AM
$CRBU Yesterday, they released first quarter report. You guys singing Pfizer after reading it, right?
0 · Reply
Jidane
Jidane May. 8 at 11:00 AM
$CRBU Any reason Pfizer is interested in? I don’t know why people keep saying pfizer As seen in ALLO and current In vivo focused Car-T market, Market doesn’t expect Pfizer to jump in. I don’t know why people kept singing Pfizer
1 · Reply
josegodoy
josegodoy May. 8 at 10:30 AM
$CRBU if/when the buyout comes…the discount precede it An opinion
0 · Reply
biochirp
biochirp May. 8 at 12:12 AM
$CRBU few weeks from penny stock or 4$ no in between
0 · Reply
RocroBio
RocroBio May. 7 at 5:40 PM
$BEAM $CRBU $EDIT $NTLA
0 · Reply
biochirp
biochirp May. 7 at 1:27 AM
$CRBU so the Pfizer option expires in June?
2 · Reply
Windytimes
Windytimes May. 6 at 11:51 PM
$CRBU this is just depressing
0 · Reply
SuperGreenToday
SuperGreenToday May. 6 at 11:14 AM
$CRBU Share Price: $1.92 Contract Selected: Oct 16, 2026 $0.5 Calls Buy Zone: $1.11 – $1.37 Target Zone: $1.78 – $2.17 Potential Upside: 51% ROI Time to Expiration: 162 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
Jidane
Jidane May. 6 at 10:37 AM
$CRBU South Korean stocks and taiwan. Woh I’m not sure he can pronounce our country’s companies name.
0 · Reply
Jidane
Jidane May. 6 at 10:33 AM
$CRBU Now He even mentioning South Korea stock. I’m south korean hahahahahaha. 200%?
0 · Reply